Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.

Pharmacological research - 1 Apr 2007

Zuccaro Piergiorgio, Mombelli Giuliana, Calabresi Laura, Baldassarre Damiano, Palmi Ilaria, Sirtori Cesare R

Abstract excerpt

Statin therapy, although generally well tolerated, leads not infrequently to significant subjective and at times objective adverse effects (AEs), mainly of a muscular nature. The genetic background of these AEs is not clear and possibly side effects and lipid lowering efficacy may be linked. Aim...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C9
Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Acids, Monounsaturated

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypercholesterolemia

Share to Muscular Diseases

Share to Simvastatin

Source

Identifiers

PMID: 17289397
DOI: 10.1016/j.phrs.2006.12.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17289397-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.PMID 17289397Read ↗

Clinical implications of pharmacogenetic variation on the effects of statins.Semantic proximity Read ↗

Liver and Statins: A Critical Appraisal of the Evidence.Semantic proximity Read ↗

Approach to clinical and genetic characterization of statin-induced myopathy.Semantic proximity Read ↗

Statin myotoxicity: a review of genetic susceptibility factors.Semantic proximity Read ↗

The genetics of statin-induced myopathy.Semantic proximity Read ↗

Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.Semantic proximity Read ↗

Pharmacogenetics of Statin-Induced MyotoxicitySemantic proximity Read ↗

CYP2D6*4 polymorphism is associated with statin-induced muscle effects.Semantic proximity Read ↗

Statin-associated muscle toxicity : clinical and genomic perspectivesSemantic proximity Read ↗

Pharmacogenomic insights into treatment and management of statin-induced myopathySemantic proximity Read ↗

Statin-associated myopathy: from genetic predisposition to clinical management.Semantic proximity Read ↗

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle ComponentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.